NASDAQ : XTLB
XTL Biopharmaceuticals Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.61 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.90M |
| Enterprise Value | 5.83M |
Dates
| Measure | Value |
|---|
| Earnings Date | Jun 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 982.99M |
| Shares Change (YoY) | +52.32% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.85% |
| Owned by Institutions (%) | 0.37% |
| Float | 942.32M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.40 |
| Quick Ratio | 0.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -209.29 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -29.30% |
| Return on Assets (ROA) | -21.01% |
| Return on Invested Capital (ROIC) | -34.43% |
| Return on Capital Employed (ROCE) | 576.77% |
| Weighted Average Cost of Capital (WACC) | 6.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.39M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -60.28% |
| 50-Day Moving Average | 2.23 |
| 200-Day Moving Average | 2.72 |
| Relative Strength Index (RSI) | 38.41 |
| Average Volume (20 Days) | 8,408 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4,178 |
| Short Previous Month | 6,050 |
| Short % of Shares Out | 0.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.51 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.47M |
| Pretax Income | -759,000 |
| Net Income | -6.97M |
| EBITDA | -1.27M |
| EBIT | -1.47M |
| Earnings Per Share (EPS) | -$3.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 76,000 |
| Total Debt | n/a |
| Net Cash | 76,000 |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | -254,000 |
| Book Value Per Share | -0.00 |
| Working Capital | -254,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -1.03M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 199,000 |
| Net Borrowing | 208,000 |
| Free Cash Flow | -1.03M |
| FCF Per Share | -$0.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -52.32% |
| Shareholder Yield | -52.32% |
| Earnings Yield | -186.99% |
| FCF Yield | -17.36% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 25, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |